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Abstract
Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular
disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite
rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known
CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of
computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist
in disease coding systems, they are often invisible in clinical records and inadequately annotated in information
systems, and features that apply to one disease but not another cannot be adequately differentiated.
Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases
and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level
classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically
understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-
aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and
ascribe relevant expert knowledge to each.
Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way
that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems.
Our classification provides a comprehensive view of the individual CMS entities in a manner that supports
differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables
robust computational coding and hierarchy for machine-readability. It can be extended as required in the light
of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible,
Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.
Keywords: Congenital myasthenic syndromes, CMS, Neuromuscular junction, Neuromuscular disease,
Nomenclature, Ontology, Nosology, Coding, Classification, Rare disease
Background
Congenital myasthenic syndromes (CMS) are rare inher-
ited neuromuscular disorders characterized by fatigable
weakness of skeletal muscle owing to compromised func-
tion of the neuromuscular junction (NMJ). First described
in the 1940s [1] as a potential rare “familial” form of
infantile myasthenia contrasting with the more common
autoimmune-mediated myasthenia gravis, the first genetic
defects associated with the condition were reported in the
1990s [2]. With the advent of next-generation sequencing
(NGS), the number of genetic defects reported as causa-
tive of a CMS phenotype has increased dramatically, with
as many as 31 genes now implicated [3]. The known types
of CMS range in frequency from more than 1000 individ-
uals to single sporadic reported cases, and around 20 to
40% of cases remain without a genetic diagnosis after
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exome sequencing [3]. Although all CMS share the com-
mon features of NMJ pathology and fatigable weakness,
the severity of the disease, its course of progression, spe-
cific phenotypic manifestations and even effective treat-
ments are highly variable between the different types.
Furthermore, different pathogenic changes within the
same gene may result in different pathological processes
and therefore markedly different disease manifestations
and therapeutic options [4].
Within this complex environment, it is clear not only
that precision in diagnosis is important in order to cor-
rectly define the disease and institute appropriate treat-
ment, but that precision in coding or classification of
this diagnosis is a prerequisite for any attempt at sys-
tematizing knowledge and linking it to a specific CMS
type. Yet coding and classification has long been a
vexed issue in the rare disease field as a whole, going
far beyond CMS [5]. Where clinical or genetic entities
do not have a named entry in disease coding systems,
they are often invisible in clinical records and inad-
equately annotated in information systems, since fea-
tures that apply to one disease but not another cannot
be adequately differentiated [6].
Coinciding with the dramatic increase in genomic
data and computational approaches to diagnosis, recent
years have seen the emergence of new data science ap-
proaches and their application to clinical problems to
allow the systematization of existing and newly gener-
ated clinical knowledge in a way that is more accessible
to computational analysis. This has been termed the
FAIR data approach, an acronym that stands for Find-
able, Accessible, Interoperable and Reusable and repre-
sents the concept that the utility of clinical and
research data is dramatically increased if it can be made
accessible to reuse by others [7]. Precision in nomen-
clature terms is just one aspect of making a dataset
FAIR, but nevertheless a crucial one in order to attach
the right knowledge to the right disease. Our present
study aimed to create a comprehensive classification for
all CMS disease entities as a starting point that will
then allow generation of FAIR-compliant datasets of
knowledge about each type.
Methods
We began by defining the CMS disease entities to be
considered in the classification. We adopted a broad
definition of CMS as any genetic neuromuscular condi-
tion manifesting with fatigable weakness of skeletal
muscle and apparent NMJ involvement. We defined in-
dividual CMS “unique entities” at (a) gene level in cases
where the presumed pathomechanism is identical for
defects anywhere in a given gene, or (b) sub-gene level
in cases where different defects in different regions of
the same gene result in different disease manifestations
due to differing pathomechanisms (e.g. to differentiate
slow-channel from fast-channel syndromes within the
same acetylcholine receptor gene). We did not split the
classification to account for variable severity, age of on-
set or incomplete penetrance of phenotypic features
where the underlying pathomechanism is the same, and
we excluded non-CMS presentations of disorders
caused by defects in the same genes that may also cause
CMS presentation (e.g. kidney presentations of LAMB2
defects). In the case of genetic entities affecting ubiqui-
tous metabolic pathways (glycosylation defects, mito-
chondrial defects), some specific mutations cause a
primary neuromuscular transmission defect, and these
are included in our classification, while other mutations
cause wider organ involvement, where the neuromus-
cular transmission defect may become irrelevant or not
detectable (e.g. syndromic congenital disorders of gly-
cosylation, encephalomyopathy), and these are then
classified elsewhere.
The entities thus defined therefore aim to be those
that from a data science perspective are sufficiently
granular to allow the mapping of disease to feature and
extend the range of knowledge about that specific dis-
ease entity. Based on this framework, through a litera-
ture review we developed a comprehensive listing of all
unique CMS clinical and genetic entities described to
date that met our criteria for inclusion. We captured the
range of terminology used in the literature to describe or
name each entity or group of entities. Using their pub-
licly available online browsers, we then reviewed the
most widely used medical and genetic coding systems to
establish their coverage of these published CMS disease
entities. Table 1 provides details of the coding systems
analyzed, the browsers used and the summary results of
the search.
From the results of the initial stage of the research,
we concluded that all existing coding systems had
major gaps in coverage, in most cases caused by inad-
equate levels of granularity, with the most granular en-
tities either completely or partially absent. Given the
pressing need to define a fully granular classification
for the “data science” purposes described above, we ini-
tiated a collaboration with Orphanet to extend the
Orphanet nomenclature [8] to include our unique CMS
disease entities. We aimed to avoid creation of a com-
peting classification given the multiplicity of systems
already in existence, and Orphanet was selected as the
most suitable system for this collaboration because it
aims to be a fully comprehensive coding system specif-
ically designed for rare disease; it makes use of a hier-
archical system or tree-like structure in which disease
entities can be grouped in different logical ways; it
includes mappings to many other coding systems at
appropriate levels of granularity thus ensuring
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interoperability [9]; and it welcomes collaborations with
domain experts for the purposes of extending its no-
menclature. Orphanet has published a procedural docu-
ment [10] for rare disease nomenclature in English that
provides detailed guidance for naming entities, which
states that names should be based on clinical practice,
validated by experts in the field, comprehensive, con-
sistent, and as stable as possible with regard to evolu-
tion of scientific knowledge. We therefore defined
“descriptive names” for each entity in a manner consist-
ent with the Orphanet guidelines, creating a clinically
understandable name for each entity that should be
stable notwithstanding the rapid advances in under-
standing the genetics of CMS. It is important to note
that while the descriptive names are valuable from the
perspective of human understanding, the essential
point is that the disease entities are assigned unique
identifiers within the coding system, which enables
computer-readability and interoperability with other
systems.
At the initial stage, the full listing of unique clinical
entities that are classed as a CMS according to our def-
inition is a non-hierarchical nosology or “flat” table
(Table 2) mapped to the existing coding systems as ap-
propriate. However, since Orphanet allows the creation
of a hierarchical classification in which individual disor-
ders may be grouped into one or multiple parent groups
based on specific features, we also created an additional
table in which we grouped all the unique entities from
Table 2 based on etiological or other features (Table 3).
Results
We defined a total of 39 unique clinical/genetic CMS en-
tities and provided descriptive names for each (Table 2).
These were mapped to existing OMIM and Orphanet
classifications and existing expert-defined descriptive
terms for each were captured from the literature to aid in
the definition of group-level classification. Treatment op-
tions were obtained from the literature [4, 11] and out-
lined in Table 2. We then placed the defined entities
within the Orphanet classification and hierarchy below
the pre-existing entry for congenital myasthenic syn-
drome, modifying one existing class name and adding 10
group-level phenotypic classes at various levels of the hier-
archy and 39 unique disease entities (Table 3).
Discussion
CMS is classed within the European Union as a rare dis-
ease (defined as one that affects fewer than 1 in 2000 in-
dividuals) and many of the individual CMS entities are
ultra-rare. This has substantial implications for know-
ledge management, since while much highly expert
knowledge on CMS does exist, in common with many
other rare diseases this knowledge is often “siloed” in in-
dividual research or clinical databases in a few expert
centers [12]. Academic publishing still largely relies on
Table 1 Coverage of congenital myasthenic syndromes by the major medical coding systems
Coding system Terminology browser used Coding for congenital
myasthenic syndromes
class/category
Coding for individual CMS types
International Classification of
Disease (ICD) Revision 11
https://icd.who.int/browse11/l-m/en 8C61: Congenital myasthenic
syndromes
No coding but textual description of
four categories:
Congenital myasthenic syndrome with
presynaptic defect, Synaptic basal
lamina-associated CMS, Congenital
myasthenia with postsynaptic defect,
CMS with glycosylation
deficiency, Unidentified CMS.
International Classification of
Disease (ICD) Revision 10
http://apps.who.int/classifications/
icd10/browse/2016/en
G70.2: Congenital and
developmental myasthenia
Not present
Medical Subject Headings
(MeSH)
https://meshb.nlm.nih.gov/search C16.320.590: Myasthenic
Syndromes, Congenital
Not present
Systematized Nomenclature
of Medicine – Clinical Terms
(SNOMED CT)
http://browser.ihtsdotools.org/ 230672006: Congenital
myasthenia (disorder)
Not present
Orphanet nomenclature
of rare diseases
https://www.orpha.net/consor/cgi-
bin/Disease.php?lng=EN
ORPHA:590: Congenital
myasthenic syndrome
Most granular level is absent. Subclasses
are defined:
Postsynaptic congenital myasthenic syndromes
Presynaptic congenital myasthenic syndromes
Synaptic congenital myasthenic syndromes
Congenital myasthenic syndromes with
glycosylation defect
Online Mendelian Inheritance
in Man (OMIM)
http://omim.org/ N/A Coding of 28 out of 39 entities with “phenotype
MIM number” (for detail see Table 2)
No hierarchies/ontological features
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Table 3 Proposed revision of Orphanet hierarchy below ORPHA:590 (Congenital myasthenic syndrome)
ORPHA
number
Typology Root Level 1 Level 2 Level 3 Level 4
ORPHA:590 Group of
phenomes
Congenital
myasthenic
syndrome
ORPHA:98913 Group of
phenomes
Postsynaptic
congenital
myasthenic
syndromes
NEW Group of
phenomes
Congenital myasthenic
syndromes with kinetic
defect
NEW Group of
phenomes
Fast-channel congenital
myasthenic syndromes
NEW Disease Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in
CHRNA1
NEW Disease Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRNB1
NEW Disease Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRND
NEW Disease Fast-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRNE
NEW Group of
phenomes
Slow-channel congenital
myasthenic syndromes
NEW Disease Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRNA1
NEW Disease Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in
CHRNB1
NEW Disease Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRND
NEW Disease Slow-channel congenital
myasthenic syndrome due to
an acetylcholine receptor
defect caused by a
pathogenic variant in CHRNE
NEW Group of
phenomes
Congenital myasthenic
syndromes with kinetic defect
due to reduced ion channel
conductance
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Table 3 Proposed revision of Orphanet hierarchy below ORPHA:590 (Congenital myasthenic syndrome) (Continued)
ORPHA
number
Typology Root Level 1 Level 2 Level 3 Level 4
NEW Disease Congenital myasthenic
syndrome with kinetic defect
due to reduced ion channel
conductance caused by
pathogenic variants in
CHRNE
NEW Group of
phenomes
Congenital myasthenic
syndromes with primary
acetylcholine receptor
deficiency
NEW Disease Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in
CHRNA1
NEW Disease Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in
CHRNB1
NEW Disease Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in CHRND
NEW Disease Congenital myasthenic
syndrome due to primary
acetylcholine receptor
deficiency caused by
pathogenic variants in CHRNE
NEW Group of
phenomes
Congenital myasthenic
syndromes due to
primary or secondary
defects in acetylcholine
receptor clustering
NEW Disease Congenital myasthenic
syndrome due to defects in
acetylcholine receptor
clustering caused by
pathogenic variants in CHRND
NEW Disease Congenital myasthenic
syndrome due to endplate
rapsyn deficiency caused by
pathogenic variants in RAPSN
NEW Group of
phenomes
Congenital myasthenic
syndromes due to
defects in endplate
development and
maintenance
NEW Disease Congenital myasthenic
syndrome due to agrin
deficiency caused by
pathogenic variants in AGRN
NEW Disease Congenital myasthenic
syndrome due to defects in
low-density lipoprotein
receptor-related protein 4
caused by pathogenic vari-
ants in LRP4
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Table 3 Proposed revision of Orphanet hierarchy below ORPHA:590 (Congenital myasthenic syndrome) (Continued)
ORPHA
number
Typology Root Level 1 Level 2 Level 3 Level 4
NEW Disease Congenital myasthenic
syndrome due to defects in
muscle-specific kinase caused
by pathogenic variants in
MUSK
NEW Disease Congenital myasthenic
syndrome due to defects in
docking protein 7 caused by
pathogenic variants in DOK7
NEW Disease Congenital myasthenic
syndrome due to plectin
deficiency caused by
pathogenic variants in
PLEC1
NEW Disease Congenital myasthenic
syndrome due to a
sodium channel 1.4
defect caused by
pathogenic variants in
SCN4A
ORPHA:98914 Group of
phenomes
Presynaptic
congenital
myasthenic
syndromes
NEW Group of
phenomes
Congenital myasthenic
syndromes due to
defective axonal transport
NEW Disease Congenital myasthenic
syndrome due to a defect in
Myosin 9A caused by
pathogenic variants in MYO9A
NEW Group of
phenomes
Congenital myasthenic
syndromes due to
defective synthesis or
recycling of acetylcholine
NEW Disease Congenital myasthenic
syndrome due to endplate
choline acetyltransferase
deficiency caused by
pathogenic variants in CHAT
NEW Disease Congenital myasthenic
syndrome caused by
pathogenic variants in PREPL
that predict reduced filling of
synaptic vesicles with ACh
NEW Disease Congenital myasthenic
syndrome due to a choline
transporter defect caused by
pathogenic variants in SLC5A7
NEW Disease Congenital myasthenic
syndrome due to a vesicular
acetylcholine transporter
defect caused by pathogenic
variants in SLC18A3
NEW Group of
phenomes
Congenital myasthenic
syndromes due to
defective synaptic
vesicles exocytosis
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Table 3 Proposed revision of Orphanet hierarchy below ORPHA:590 (Congenital myasthenic syndrome) (Continued)
ORPHA
number
Typology Root Level 1 Level 2 Level 3 Level 4
NEW Disease Congenital myasthenic
syndrome due to a
synaptosomal-associated pro-
tein 25 defect caused by
pathogenic variants in
SNAP25B
NEW Disease Congenital myasthenic
syndrome due to a
synaptotagmin defect caused
by a pathogenic variant in SYT2
NEW Disease Congenital myasthenic
syndrome due to a
mammalian uncoordinated-13
protein defect caused by a
pathogenic variant in UNC13A
NEW Disease Congenital myasthenic
syndrome due to a vesicle
associated membrane protein
1 defect caused by a
pathogenic variant in VAMP1
NEW Disease Congenital myasthenic
syndrome due to a
mitochondrial citrate
carrier defect caused by
pathogenic variants in
SLC25A1
ORPHA:98915 Group of
phenomes
Synaptic and
basal lamina
associated
congenital
myasthenic
syndromesa
NEW Disease Congenital myasthenic
syndrome due to endplate
acetylcholinesterase
deficiency caused by
pathogenic variants in COLQ
NEW Disease Congenital myasthenic
syndrome due to collagen 13
defects caused by pathogenic
variants in COL13A1
NEW Disease Congenital myasthenic
syndrome due to laminin
beta 2 deficiency caused by
pathogenic variants in LAMB2
ORPHA:353327 Group of
phenomes
Congenital
myasthenic
syndromes
with
glycosylation
defect
NEW Disease Congenital myasthenic
syndrome due to a
defect of glycosylation
caused by pathogenic
variants in GFPT1
NEW Disease Congenital myasthenic
syndrome due to a
defect of glycosylation
caused by pathogenic
variants in DPAGT1
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“non-machine-readable” formats such as PDF and this
again provides a barrier to easy access and reuse [13]. This
means that not only do fewer clinicians who encounter
CMS patients have the relevant experience themselves,
but it is also more challenging and time-consuming for
them to locate the information they need.
Clinical, genetic and scientific experts in CMS have
come together periodically to review and update classifica-
tions of the disease at workshops hosted by the European
Neuromuscular Centre [14–16], in NCBI’s GeneReviews
series [17] and several comprehensive recent review publi-
cations [3, 4, 18]. Broad classifications of CMS into pre-
synaptic, synaptic and postsynaptic CMS and CMS with
glycosylation defect were originally proposed in 2001 [15],
but it is only with the very latest update to the Inter-
national Classification of Disease (ICD), Revision 11 [19],
that these subgroups even receive a mention (without,
however, being allocated a classification number). Mean-
while, as the number and variety of CMS disease entities
published in the literature has increased, expert-proposed
groupings have been extended to include a new group
containing defects of endplate development and mainten-
ance [18]. However, the expert reviews have not attempted
any standardization of nomenclature in the coding sys-
tems, and at the most granular level, individual “atomic”
disease entities or subtypes are conspicuous in their ab-
sence from all the coding systems except the Online Men-
delian Inheritance in Man (OMIM) database [20]. OMIM
itself has good (although not entirely comprehensive)
coverage of the individual disease entities, each repre-
sented by a “phenotype MIM number” and a sequentially
numbered name, and is recognized as the authoritative ref-
erence for genetic disorders, but is not itself a nosology or
ontology but rather a catalogue, which is thus complemen-
tary to (and mappable to) the classification we create here.
To counter the problem of lack of representation of rare
disease entities in knowledge systems, bringing data
science approaches into the clinical domain has been the
focus of a number of recent activities at the European and
international level, including the Global Alliance for Gen-
omics and Health (GA4GH) [21], the European Open Sci-
ence Cloud [22], Big Data to Knowledge (BD2K) [23], the
Monarch Initiative [24], GO-FAIR [25], RD-Connect [26]
and the new European Joint Programme for Rare Disease
to be launched in 2019. Making use of ontologies and cod-
ing systems when capturing clinical information and diag-
noses is a key step in preparing data for reanalysis and
machine-readability [27], but in order for this to be of
benefit, the coding system must be fit for purpose – which
means it must contain the relevant items in the correct
relative positions and at appropriate levels of granularity. If
this is not the case, data cannot be appropriately con-
nected or connections may produce misleading results.
For example, to a clinician familiar with CMS, it goes with-
out saying that the connection between “congenital myas-
thenic syndrome” and “responsive to pyridostigmine” is
true for CMS caused by RAPSN defects and false for that
caused by defects in DOK7, but a database that only con-
tains an entry for “congenital myasthenic syndrome” has
no way of making that distinction. The result of this is that
the specific knowledge that is so familiar to the disease ex-
perts cannot easily gain wider currency by being made part
of online databases or clinical decision support systems,
and furthermore the evidence gathered in a clinical setting
in support of particular interventions or particular pheno-
typic associations cannot be fed back into wider practice
by from medical or prescribing records, for example.
Of course, no classification in such a rapidly evolving
and heterogeneous field can ever be completely compre-
hensive, and there are always areas where different deci-
sions could be made, such as about the level of granularity
or the range of conditions to include. Our inclusion
criteria were based primarily on clinical and phenotypic
presentation together with some pathomechanistic
Table 3 Proposed revision of Orphanet hierarchy below ORPHA:590 (Congenital myasthenic syndrome) (Continued)
ORPHA
number
Typology Root Level 1 Level 2 Level 3 Level 4
NEW Disease Congenital myasthenic
syndrome due to a
defect of glycosylation
caused by pathogenic
variants in ALG2
NEW Disease Congenital myasthenic
syndrome due to a
defect of glycosylation
caused by pathogenic
variants in ALG14
NEW Disease Congenital myasthenic
syndrome due to a
defect of glycosylation
caused by pathogenic
variants in GMPPB
aname of group updated from “synaptic congenital myasthenic syndromes”
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insights, while a purely gene-based approach might have
produced a classification not exclusively including CMS
presentations but also kidney or skin disease presentations
caused by different defects in the same genes. In addition,
there are other neuromuscular conditions that do have de-
tectable morphological and functional disturbances of the
neuromuscular junction, but where these are considered
to be secondary to the primary pathology or of minor clin-
ical relevance as compared to the primary clinical mani-
festation (e.g. spinal muscular atrophy or myotubular
myopathy). These conditions are classified in different sys-
tems and do not appear in our CMS classification. How-
ever, from a data science perspective, the choice of what
to include or exclude can indeed be left to expert opinion
and is of secondary importance compared to the depth
and detail of what is covered, and crucially, its internal
logic and relationships with other entities and other classi-
fication systems [27]. The CMS entities that we have de-
fined fit perfectly as subclasses within the broader coding
systems like ICD and SNOMED-CT and map at a 1:1 level
to the phenotype MIM numbers where these exist (see
Table 2). They can be grouped into preexisting etiological
groups such as pre- and post-synaptic (Table 3), and are
amenable to multiple other functional, phenotypic and
therapeutic groupings as appropriate (“responsive to
acetylcholinesterase inhibitors”, “with limb-girdle pheno-
type”, “associated with episodic apnea” or “characterized
by tubular aggregates”, for example).
To take full advantage of the classification developed
here, it will be necessary that these next steps are taken,
since the development of classification systems, even with
names that aim to have some clinical relevance, is of lim-
ited diagnostic or therapeutic value in itself. Rather, it
should be thought of as the essential foundation onto
which more precise clinical and diagnostic pictures of each
disease entity can be built, and it is this systematization of
knowledge that can then be brought back into the diag-
nostic and clinical arena to result in improved diagnostic
algorithms and clinical information systems. One future
development well supported by Orphanet that is a logical
extension of the classification to allow improved diagnostic
algorithms is the mapping of entities from the classifica-
tion to their individual phenotypic features using appropri-
ate phenotypic descriptors from ontologies such as the
Human Phenotype Ontology [28]. This creates a matrix of
detailed information about each disease entity in both
computer-accessible and human-readable formats, and is
something that can now be achieved for CMS by a similar
consensus process. In addition, since many CMSs are
treatable, but the treatment varies by type, we can use the
classification to differentiate treatments by type as shown
in Table 3 and also now have the opportunity to take this
further in a machine-readable manner through the devel-
opment of pharmacogenomic algorithms that give
clinicians easier access to specific treatment recommenda-
tions once a particular CMS type has been identified. Fur-
thermore, although NGS techniques have still not solved
every CMS case, as science advances, we can expect that
new genetic defects will be uncovered that account for
some of the remaining undiagnosed congenital myasthenic
syndromes, and we have thus ensured that this present
classification can easily be extended with new entities.
Conclusions
Knowledge about the full range, etiology and heterogen-
eity of the congenital myasthenic syndromes has increased
rapidly in the NGS era. These diseases present specific
challenges owing to their rarity and heterogeneity but also
possess certain features – not the least of which is respon-
siveness to treatment – that make their unambiguous dif-
ferentiation worthwhile. The benefits of developing a fully
granular classification for this group of conditions are thus
not purely academic. Although not designed as a diagnos-
tic tool, the detailed classification in a single system of
each individual CMS with a defect of neuromuscular
transmission as the primary feature provides clinicians
and geneticists with an overview of the currently recog-
nized congenital myasthenic syndromes both as individual
entities and as logical groupings and this can provide
guidance towards the differential diagnoses for a patient
with a broad CMS phenotypic presentation. Making use
of an unambiguous clinically understandable descriptive
name assists in the clinical differentiation of the different
diseases, particularly by clinicians less familiar with these
rare conditions, while attaching the descriptive name to a
code within a recognized coding system enables exist-
ing knowledge to be better systematized, thus paving
the way towards computer-aided clinical systems and
machine-learning algorithms suitable for the NGS era.
Through this collaboration between clinical experts and
data science experts, we have shown that data science
approaches can be used effectively in the clinical do-
main in a way that does not disrupt preexisting classifi-
cation by experts and that enhances the utility of
preexisting coding systems, building on both to create a
more comprehensive result. The classification we have
defined can be used in clinical administration systems
as an integral part of the Orphanet nomenclature and
can be used in scientific publications and clinical case
reports to unambiguously define the CMS type in ques-
tion. It can be extended and modified as required by fu-
ture scientific advances, but already provides the starting
point for the creation of FAIR knowledge bases of data re-
lated to the congenital myasthenic syndromes.
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